Drug intelligence / Profile preview

evatanepag

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules

Overview

Evatanepag is a small molecule drug that acts as a selective agonist of the prostaglandin E2 EP2 receptor (PTGER2). It was developed primarily for its ability to stimulate new bone formation on trabecular, endocortical, and periosteal surfaces. Preclinical studies demonstrated that local administration of evatanepag could induce bone formation and enhance fracture healing. The drug was investigated in clinical trials for the treatment of tibial fractures and osteoporosis but has not been approved for any indication. Pfizer was the primary developer of this compound[1][3][7][9].

Other names: evatanepag sodium

Targets

PTGER2 (Prostaglandin E2 receptor EP2)

Beyond the preview

Go deeper on evatanepag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on evatanepag.

Explore the full profile